(Q40253273)

18 September 2017

1 reference

title

Verapamil hydrochloride: pharmacological properties and role in cardiovascular therapeutics (English)

1 reference

18 September 2017

1 reference

Baky SH

1

1 reference

18 September 2017

Singh BN

series ordinal

2

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 November 1982

1 reference

18 September 2017

1 reference

18 September 2017

volume

2

1 reference

18 September 2017

issue

6

1 reference

18 September 2017

page(s)

328-353

1 reference

Cardiac muscle: excitability and passive electrical properties

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Fluorometric Assay of Verapamil in Biological Fluids and Tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

GLC Assay of Verapamil in Plasma: Identification of Fluorescent Metabolites after Oral Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil kinetics in normal subjects and patients with coronary artery spasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Comparative Mechanisms for Contraction of Cardiac and Skeletal Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Calcium Channel Blocking Agents in the Treatment of Cardiovascular Disorders. Part I: Basic and Clinical Electrophysiologic Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Specific Pharmacology of Calcium in Myocardium, Cardiac Pacemakers, and Vascular Smooth Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibres by the use of specific inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Selective suppression of some components of spontaneous activity in various types of smooth muscle by iproveratril (Verapamil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

The effect of verapamil on the Ca2+-transporting and Ca2+-ATPase activity of isolated cardiac sarcolemmal preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Inhibitory activity of blockers of the slow inward current in rat myocardium, a study in steady state and of rate of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Quantitative differences between the inhibitory action of verapamil and Ni ions on the slow response action potential in mammalian ventricular myocardium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of agents which inhibit the slow channel on sinus node automaticity and atrioventricular conduction in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on ventricular rhythm during acute coronary occlusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Electrophysiologic and hemodynamic effects of verapamin. Correlation with plasma drug concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Action of verapamil on sinus node, atrioventricular, and intraventricular conduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effect of verapamil on normal sinoatrial node function and on sick sinus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effect of nifedipine on atrioventricular conduction as compared with verapamil. Intracardiac electrophysiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Comparative clinical electrophysiologic effects of diltiazem, verapamil and nifedipine: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Haemodynamic effects of intravenous verapamil at rest and during exercise in subjectively healthy middle-aged men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of intravenous verapamil on hemodynamics in patients with heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on myocardial performance in coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on infarct size following experimental coronary occlusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

The Effect of Verapamil on Experimental Myocardial Ischaemia with a Particular Reference to Regional Myocardial Blood Flow and Metabolism*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Reduction of the size of acute, experimental myocardial infarction by Verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Hypothesis and provocations. What is the evidence for and the significance of spasm in acute myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

21 January 2018

Coronary-Artery Spasm

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Variant angina pectoris: Investigation of indexes of sympathetic nervous system function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Exacerbation of vasotonic angina pectoris by propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of ergonovine in patients with and without coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Provocative testing with ergonovine to evaluate the efficacy of treatment with calcium antagonists in variant angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Management of unstable angina at rest by verapamil. A double-blind cross-over study in coronary care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

The injury-spasm (ischemia-induced hemostatic vasoconstrictive) and vascular autoregulatory hypothesis of ischemic disease. Resistance vessel-spasm hypothesis of ischemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effect of drugs on conduction delay and incidence of ventricular arrhythmias induced by acute coronary occlusion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

New perspectives in the pharmacologic therapy of cardiac arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil: a review of its pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Clinical pharmacology of slow channel blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on supraventricular tachycardia in patients with overt and concealed Wolff-Parkinson-White syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Immediate effects of intravenous verapamil on atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Electrophysiologic properties and response to pharmacologic agents of fibers from diseased human atria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Treatment of hypertrophic obstructive cardiomyopathy with verapamil, a calcium antagonist (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Physiological disposition of verapamil in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single i.v. and oral administration and during chronic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

Verapamil in stable effort angina: Effects on left ventricular function evaluated with exercise radionuclide ventriculography

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1875-9114.1982.TB03210.X

10.1002/J.1875-9114.1982.TB03210.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference